Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Bullboard Posts
Comment by thadeushon Dec 03, 2016 8:22pm
79 Views
Post# 25551450

RE:Comparing Resource Companies to GEN

RE:Comparing Resource Companies to GENPretty casual use of "freefall." I've seen freefalls and so have you, I bet, and this wasn't a freefall. This was a low volume pullback to a fib line - and it was needed to get back on trend. Indicators are just now getting to where they need to be. In fact, I still think we may need to see .30-.32 before GEN can head north.

Not sure how this nr will be perceived by the market on Monday, but it should be neutral or, for those that really get it (raising needed funds without dilution and negative effect on the sp), positive. They were wise to release this on a Friday as many, including me, needed to jump on the learning curve to understand that it is a big positive for the company. We'll see, gluck to all.
Bullboard Posts